Navigation Links
hKv4.2/hKChIP2-CHO K1 Recombinant Cell Line from Upstate

ProductshKv4.2/hKChIP2-CHO K1 Recombinant Cell Line from Upstate
Company Upstate
Item hKv4.2/hKChIP2-CHO K1 Recombinant Cell Line
Price 
Description PrecisION Ion Channel Cell Lines
High Quality, Functionally-Validated, Ion Channel Cell Lines

Ion channels are well known for having a critical role in nerve and muscle function and consequently have a key function in pain, CNS and the heart. Drugs that modulate ion channels have been investigated in therapeutic areas, such as neuropathic pain, cardiac arrhythmia, hypertension, local anaesthesia, stroke, Parkinson's, obesity, epilepsy, diabetes and depression.

Historically, ion channels have been under exploited as drug targets primarily due to the lack of functional high throughput screening technologies. Over recent years, there has been considerable progress in this important area. However, now there is a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry.

Our ion channel cell lines are available off of the shelf. These cell lines are fully validated using electrophysiology, stable (>25 passage) and licensed for drug discovery research. The objective is to provide the pharmaceutical industry with a range of ion channel cell lines to support drug discovery, lead optimisation and safety pharmacology functions.
Info UpstateUpstate
28820 Single Oak Drive
Temecula, CA 92590
Customer Service: 800-437-7500 or 951-676-8080
Tech Support: 800 548-7853
Fax Number: 800-437-7502 or 951-676-9209
Web Site: http://www.upstate.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Recombinant Expression of Peptides and Proteins: from rPeptide, LLC
2. Recombinant RNasin® Ribonuclease Inhibitor from Promega
3. GeneChoice RNA Safe Recombinant Ribonuclease Inhibitor from GeneChoice, Inc.
4. RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen
5. hERG-CHO K1 Recombinant Cell Line from Upstate
6. hERG-CHO K1 Recombinant Cell Line from Upstate
7. hHCN4-CHO K1 Recombinant Cell Line from Upstate
8. hKv1.5-CHO K1 Recombinant Cell Line from Upstate
9. hNav1.6-HEK293 Recombinant Cell Line from Upstate
10. hKvLQT1/hminK-CHO K1 Recombinant Cell Line from Upstate
11. Smac/DIABLO, Human, Recombinant, E. coli from Calbiochem
Direct ELISA Assay Diluent from BioFX Laboratories, Inc.
Assay Diluent Trial Pack from BioFX Laboratories, Inc.
UNICO Spectrophotometer from Femto Scientific
SuperScript Indirect cDNA Labeling System from Invitrogen
Biology Products:
(Date:11/20/2009)...hed in the November 2009 issue of the journal GEN...w how a family of genes (1-aminocyclopropane-1-car...or production of ethylene. This gas affects many a...lays the foundation for future genetic manipulatio...o survive and thrive in difficult terrain, increas...
(Date:11/20/2009)... 2009) Scientists from the Marine Biogeochemistry...Research Laboratory (NRL) organized and led a team...tic expedition to initiate methane hydrate explora... variation of sediment contribution to Arctic clim...ter Polar Sea as a research platform, three cross-...
(Date:11/20/2009)... - Bacteria possess an ingenious mechanism for pre... the cell. This is the new finding of a team of bi...e sciences research institute in Flanders, Belgium... scientists made this discovery by modifying the D... By means of this model organism, they have uncove...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2International expedition investigates climate change, alternative fuels in Arctic 2Biologists discover bacterial defense mechanism against aggressive oxygen 2Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 1Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 2Despite Generic Erosion of Key Brands the Hospital Acquired Gram Negative Infections Drug Market Will Increase by 241 Billion from 2008 to 2018 49015 3AlphaRx and Gaia BioPharma Provide GAI 122 Development Update 49013 1AlphaRx and Gaia BioPharma Provide GAI 122 Development Update 49013 2JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 1JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 2JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 3JustAnswer 28R 29 and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness 49011 4
...ial fishing operations take plenty of blame for bo...g innocent bystanders such as dolphins, sharks, se...catch." , But new research shows that a small-sca...en boats--can kill as many critically endangered l...hing fleets in the North Pacific Ocean put togethe...
... -- By peering deep into evolutionary history, sci...bara have discovered the origins of photosensitivi...this weeks issue of the scientific journal PLoS ON..., a member of Cnidaria, which are animals that hav...uthors are the first scientists to look at light-r...
...r at the Albert Einstein College of Medicine has b...development grant from the National Human Genome R...es of Health. Dr. John Greally, associate professo...n, received one of six technology development gran...a Of DNA Elements (ENCODE) project. , Dr. Greall...
Other Biology News:Small-scale fishing in Mexico rivals industrial fisheries in accidental turtle deaths 2Small-scale fishing in Mexico rivals industrial fisheries in accidental turtle deaths 3UCSB researchers discover the dawn of animal vision 2Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome 2
(Date:11/19/2009)... , MUNSTER, Germany, November 19 /PRNews... have filed on November 16th, 2009 Flibanserin in ... dyskinesia in Parkinson,s,disease for orphan drug...ency,(EMEA). Levodopa-induced dyskinesia is a comp...kinson,s and a serious burden to some of those,aff...
(Date:11/19/2009)... , VIENNA, Austria, November 19 /PRNews...cine program on one product candidate at an unexpe...didate AD02 is planned to enter into,Phase II clin...pany,immediately follows the completion of two Pha... company based its fast decision on the first inte...
(Date:11/18/2009)...entists at Queen,s University Belfast are developi...al drugs which will help in the fight against the ...use special gel pads to ,swipe, an individual or c...ed by a scanning instrument that can detect the pr...w better, faster decisions to be made in response ...
(Date:11/18/2009)... , NEW YORK, Nov. 18 Repor...eport is available in its catalogue. ,, Biote...,, http://www.reportlinker.com/p0164375/Biote...ml#utm_source=prnewswire&utm_medium=pr&utm...echnology are complex chemical compounds used in a...
Breaking Biology Technology:MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3New technology detects chemical weapons in seconds 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 3Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 4Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 5Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 6Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 7Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 8